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Background. The ob gene product leptin is thought to be a key
regulator of food intake and body weight. Patients having ad-
vanced chronic renal failure (CRF) have markedly higher serum
leptin levels. It is not known whether the increase in leptin levels
in CRF is caused by a decreased plasma clearance and/or in-
creased production.
Methods. In the present study serum leptin levels and glomer-
ular filtration rate (GFR) were measured in 219 patients having
various degrees of renal failure. In addition, serum leptin levels,
C-reactive protein (CRP), body composition (by dual-energy x-ray
absorptiometry) and ob gene expression (by in situ hybridization
histochemistry) were determined in 15 patients with advanced
CRF. Seven of the patients were re-evaluated following 12 months
of peritoneal dialysis (PD) treatment.
Results. Serum leptin levels correlated negatively to GFR (r 5
20.26; P , 0.0001). The ob gene expression was significantly
lower in patients with CRF than in healthy controls. A negative
correlation between serum leptin levels and ob gene expression
(r 5 20.66; P , 0.05) was found in patients with CRP , 25
mg/liter. The ob gene expression (20.0 6 1.8 vs. 15.0 6 1.0 nCi/g;
P , 0.05) was significantly higher in 5 patients with CRP . 25
mg/liter than in 10 patients with CRP , 25 mg/liter. Following 12
months of PD, the amount of body fat increased by 30% while the
ob gene expression remained unchanged.
Conclusion. The present study shows a correlation between
serum leptin levels and GFR, and our results suggest that elevated
leptin levels, due to a decreased plasma clearance, down-regulate
the expression of the ob gene. We also found that an ongoing
inflammation stimulates ob gene expression in patients with CRF.
Therefore, it is suggested that the hyperleptinemia induced
feedback inhibition of ob gene expression is overcome by inflam-
matory cytokines.
Leptin, the product of the ob gene [1], is a peptide
hormone produced by adipocytes that binds to specific
receptors predominantly found in the brain, from where it
suppresses appetite [2]. Very little is known about the
physiological actions of leptin in humans, but administra-
tion of recombinant leptin to ob/ob mice, which have a
genetic defect in leptin production, reduces food intake and
increases energy expenditure [3, 4].
Malnutrition due to poor food intake is a common
clinical problem in patients with advanced chronic renal
failure (CRF) [5] and is associated with increases in
morbidity and mortality [6, 7]. We [8] and others [9–12]
have recently shown that patients with advanced CRF with
[8–12] and without [8, 10, 12] ongoing dialysis treatment
have markedly elevated serum leptin levels without an
increase in body fat mass. Since leptin is thought to be an
inhibitor of appetite, by affecting the neuropeptide Y
(NPY) and/or melanocortin systems [13], it has been
speculated that elevated serum leptin levels could contrib-
ute to anorexia and poor nutrition in patients with renal
failure [12]. Moreover, as leptin receptor isoforms have
been reported in several peripheral organs it has been
speculated that leptin, besides having central effects, could
have a function also in peripheral organs [14, 15]. This
suggests that the functional role of leptin extends beyond
the regulation of feeding and metabolism to include other
organs and biological functions. As the kidneys are impor-
tant in clearing several other polypeptide hormones such as
insulin, parathyroid hormone and glucagon, it seems rea-
sonable to speculate that serum leptin also accumulates in
renal failure due to reduced renal clearance. However,
elevated serum leptin levels are not a universal finding in
advanced CRF [16] and the exact cause of elevated serum
leptin levels in uremia is not well understood, although
there are data suggesting that a decrease in glomerular
filtration rate [10, 11, 17, 18], inflammation [8] and hyper-
insulinemia [16, 19] may affect this finding.
The aim of the present study was primarily to study the
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effects of moderate and advanced renal failure on serum
leptin levels in a large cohort of patients having various
degrees of renal failure. Secondly, we studied the ob gene
expression in non-obese patients with advanced renal fail-
ure and various degrees of hyperleptinemia, to test the
hypothesis that elevated serum levels of leptin down-
regulate ob gene expression. Thirdly, we investigated
whether elevated serum levels of C-reactive protein (as an
indication of ongoing inflammation) may stimulate ob gene
expression in patients with CRF. Finally, in a prospective
part of the study, we investigated the effect of 12 months of
peritoneal dialysis (PD) on body fat mass, serum leptin
levels and ob gene expression.
METHODS
The glomerular filtration rate study
In this cross-sectional study, 219 patients (130 males and
89 females) with various degrees of renal impairment were
investigated. The mean age of the male patients was 52 6
1 year (range 20 to 85 years) and their body-mass index
(BMI), defined as the weight in kilograms divided by the
square of the height in meters was 25.2 6 0.4 kg/m2 (range
14.3 to 36.5 kg/m2). The mean age of the female patients
was 52 6 2 years (range 24 to 80 years) and their BMI was
24.5 6 0.5 kg/m2 (range 16.0 to 39.7 kg/m2). Blood samples
were taken for determinations of serum leptin after an
overnight fast and GFR was measured by iohexol clearance
(N 5 157) or creatinine clearance (N 5 62). Creatinine
clearance was only used in patients with a GFR , 20
ml/min. The serum leptin concentrations were also ana-
lyzed in 50 healthy controls (mean age 44 6 1 year, range
23 to 71 years) chosen to match the patients with respect to
BMI.
Ob gene expression in chronic renal failure
Fifteen patients (8 males) with advanced CRF (creati-
nine clearance 9 6 1 ml/min) were investigated closely
prior to initiation of dialysis treatment. The mean age was
60 6 2 years and the BMI 24.4 6 1.0 kg/m2. Seven of the
patients had diabetic nephropathy, four had chronic glo-
merulonephritis, two had interstitial nephritis and two had
CRF of unknown etiology. The mean HbA1c level was
7.6 6 0.6% in the diabetic patients and 6.6 6 0.3% in the
non-diabetic patients. None of the patients were on steroids
or androgens. The subjects fasted overnight and blood
samples for analyses of serum leptin and CRP were taken.
Within three hours fat biopsies were taken in a fasting state
from the abdominal subcutaneous adipose tissue, following
local anesthesia, for determination of ob gene expression.
Body composition analysis was performed, using dual-
energy x-ray absorptiometry (DXA). Patients were divided
into two groups, one with CRP , 25 mg/liter and one with
CRP . 25 mg/liter. Five patients (2 males) had a CRP
level . 25 mg/liter, whereas 10 patients (5 males) had little
if any elevation of CRP (,25 mg/liter). The rise in CRP
levels was due to polychondritis (N 5 1) or recurrent
infections (N 5 4). A control group (52 6 3 years)
consisted of eight non-obese (BMI 22.1 6 0.6 kg/m2),
fasted but otherwise healthy subjects (4 males) undergoing
elective laparoscopic cholecystectomy at Huddinge Univer-
sity Hospital.
Changes in ob gene expression following 12 months of
peritoneal dialysis
Seven patients from the cross-sectional part of the ob
gene expression study (4 males and 3 females with CRP
levels , 25 mg/liter) were re-investigated following 12
months of PD. The mean age was 56 6 3 years and BMI
24.3 6 0.9 kg/m2. Six of the patients were treated by
continuous ambulatory peritoneal dialysis (CAPD) and one
with automated PD. Dietary recommendations were given
routinely to maintain a daily protein intake exceeding 1.0
g/kg body wt. Protein intake was monitored by urea kinetics
while energy intake was not routinely monitored. In addi-
tion to the baseline studies described above, fasting blood
samples for CRP and serum leptin were drawn in the
morning and measurements of body composition (DXA),
weight and height were made after 12 months of PD.
Following local anesthesia, fat biopsies were taken from the
abdominal subcutaneous adipose tissue for analysis of ob
gene expression. All studies were approved by the Ethics
Committee of Karolinska Institute, Stockholm, Sweden,
and all patients gave informed consent to participate in the
study.
Analyses
The serum leptin levels were analyzed with a commer-
cially available radioimmunoassay kit (Linco Research Inc.,
St. Charles, MO, USA). The leptin assay was completely
homologous, since the antibody was raised against highly
purified human leptin and both standard and tracer were
prepared with human leptin. The coefficient of variance
within the sample was 6%. Determinations of CRP,
HbA1c, serum creatinine and urinary creatinine were car-
ried out at the Department of Clinical Chemistry, Hud-
dinge Hospital, using routine methods. Creatinine clear-
ance was calculated according to the standard clearance
formula. Iohexol clearance was performed as previously
described [20]. Since the detection limit of CRP at the
Department of Clinical Chemistry, Huddinge Hospital is 10
mg/liter, all values , 10 mg/liter were treated as 9 mg/liter
in the statistical evaluation. The body composition of all
subjects in the ob gene expression studies was determined
with dual-energy x-ray absorptiometry (DXA; Lunar Corp.,
Madison, WI, USA) with Lunar software version 3.4.
Adipose tissue biopsies
The subjects fasted overnight. Patients with CRF were
locally anesthesized and intravenous saline was adminis-
tered prior to taking biopsies under local anesthesia from
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the abdominal subcutaneous adipose tissue. In controls,
consisting of otherwise healthy subjects undergoing elective
laparoscopic cholecystectomy, fat biopsies were taken fol-
lowing general anesthesia. General anesthesia was induced
at 8 a.m. by a short-acting barbiturate and maintained by
fontanel and a mixture of oxygen and nitrous oxide. Intra-
venous saline was administered before taking biopsies from
the abdominal subcutaneous tissue. The adipose tissue
specimens ranged from 200 mg to 1000 mg and were
immediately frozen unfixed on dry ice in the operating
room, whereafter they were stored at 270°C until sec-
tioned.
Preparation of gene probes
A human ob gene 48-mer oligonucleotide, complemen-
tary to nucleotides 122-169, and a sense 45-mer oligonu-
cleotide for the same region, as well as a human 48-mer
gamma-actin oligonucleotide probe, complementary to nu-
cleotides 325-372 [21], were synthesized and purified by
Pharmacia Biotech, Uppsala, Sweden. Gamma actin was
used to ensure, first, that the mRNA was of equally good
quality in all tissue samples examined and secondly, that
changes in ob mRNA were specific for the latter gene. The
oligonucleotides were subsequently given an 35S-labeled
dATP (NEG 034H; NEN DuPont, Boston, MA, USA) at
the 39 end, using terminal dideoxy nucleotidyl transferase
to a specific activity of 2 3 109 cpm/mg and purified in a
Nensorb 20 column.
In situ hybridization
Adipose tissue from all 23 subjects (CRF patients and
controls) was analyzed with respect to ob and gamma-actin
expression as previously described [22, 23]. The tissue was
rapidly frozen and subsequently cut to a thickness of 20 mm
in a cryostat, thawed onto electrically charged Fisher probe
on 1 slides (Fisher Biotech, Springfield, NJ, USA), and
processed for in situ hybridization (Fig. 1) [24]. In brief, the
sections were incubated at 42°C for 15 to 18 hours with 106
cpm of labeled probe per 100 ml of a solution containing
50% formamide, 4 3 SSC, 1 3 Denhardt’s solution, 1%
sarcosyl, 0.02 M sodium phosphate (NaPO4, pH 7.0) and
10% dextran sulfate mixed with 500 mg/ml sonicated
salmon sperm DNA and 200 mM dithiothreitol. SSC is a
solution of sodium chloride and sodium citrate, while
Denhardt’s solution is made from Ficoll 10 g, bovine serum
albumin 10 g and polyvinylpyrrolidone 10 g in 500 ml
distilled water. The sections were subsequently rinsed in
1 3 SSC at 55°C for one hour with five changes of buffer,
dried and exposed to Amersham Hyperfilm b-max x-ray
film for 14 days before development and fixation.
Quantification of in situ hybridization autoradiographs
Autoradiographic 14C microscale strips (Amersham In-
ternational, Little Chalfont, UK) ranging from 31 to 883
nCi/g were used as standards by coexposure with the tissue
sections. Slides were processed together, in triplicate, for
analysis of leptin or gamma actin and were handled as a
single batch through hybridization, washes, autoradio-
graphic exposure and computerized image analysis. Any
possible batch effect would therefore occur already at the
sectioning stage. The signals were measured from high-
resolution x-ray films, where sections had been coexposed
with radioactive standards to linearize the film response to
radiation. Results from the different measurements were
highly reproducible. This quantification was performed on
a Macintosh IIx (Apple Computer Inc., Cupertino, CA,
USA) equipped with a Quick Capture frame grabber board
(Data Translation, Marlboro, MA, USA), a Northern Light
precision illuminator (Imaging Research, St. Catherines,
Ontario, Canada) and a Hamamatsu CCD (Hamamatsu,
Hamamatsu City, Japan) camera equipped with a Nikon 55
mm lens. To process the images, Image software was used.
Fig. 1. Darkfield emulsion autoradiograph of
subcutaneous adipose tissue from a control
individual following hybridization with a
radioactive probe complementary to leptin
mRNA. Note accumulation of silver grain
towards the periphery of each cell, indicating
that most leptin mRNA is produced in a small
compartment of the cytoplasm close to the cell
membrane. There is quite intense labeling over
all adipocytes, whereas control tissues (not
shown) display only background labeling.
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Each frame was digitized to a 512 3 512 matrix with 256
gray levels for each picture element. The gray-levels, cor-
responding to the 5 standards lying within the exposure
range of the film, were determined and used in a third-
degree polynomial approximation to construct a gray-level
to activity transfer function. Slides that were not dipped in
NTB 2 nuclear track emulsion were stained by treatment
with hematoxylin and eosin.
Statistical analysis
All results are given as mean 6 SEM. The non-parametric
Mann-Whitney U-test or Student’s unpaired t-test was used
to test differences between different groups, as appropri-
ate. The non-parametric Wilcoxon rank-sum test or Stu-
dent’s paired t-test was used to evaluate differences over
time in the prospective study, as appropriate. Regression
analysis was used to test the correlation between variables.
A P value less than 0.05 was considered significant.
RESULTS
Glomerular filtration rate correlates with leptin
In the entire group of patients with various degrees of
renal impairment (N 5 219), the mean GFR was 39 6 2
ml/min (range 2 to 122 ml/min). The mean serum leptin
concentration was significantly (P , 0.0001) higher among
the renal patients (20.8 6 1.9 ng/ml) than among healthy
controls (9.0 6 1.0 ng/ml). In the entire group of renal
patients significant correlations were found between serum
leptin levels versus GFR (r 5 20.26; P , 0.0001) and BMI
(r 5 0.47; P , 0.0001), respectively, whereas no significant
correlation was observed between GFR and BMI. To
remove the variation of BMI an analysis of co-variance was
performed and a strong significant (P , 0.0002) relation
remained between log-transformed serum leptin and GFR.
Among the 130 men with renal disease, the mean GFR was
36 6 3 ml/min (range 2 to 122 ml/min). The mean serum
leptin concentration was significantly (P , 0.001) higher in
male patients (13.5 6 1.2 ng/ml vs. 4.7 6 0.4 ng/ml) than in
23 BMI-matched healthy males. Among the men significant
correlations were detected between serum leptin levels and
GFR (r 5 20.17; P , 0.05) and BMI (r 5 0.56; P ,
0.0001), respectively. No significant correlation was present
between GFR and BMI in men with renal disease. Among
the 89 females with renal disease, mean GFR was 44 6 4
ml/min (range 4 to 118 ml/min) and the mean the serum
leptin concentration was significantly higher (31.6 6 4.0
ng/ml vs. 12.6 6 1.4 ng/ml; P , 0.01) than in 27 BMI-
matched healthy females. Significant correlations were
observed between serum leptin levels and GFR (r 5 20.44;
P , 0.0001) and BMI (r 5 0.56; P , 0.0001), respectively,
also among the females. No significant correlation was
noted between GFR and BMI in females with renal
disease.
When the patients were divided into three groups ac-
cording to the degree of renal impairment (advanced renal
failure 5 GFR , 20 ml/min, moderate renal failure 5
GFR 20 to 80 ml/min, and normal renal function 5 GFR .
80 ml/min), significantly higher serum leptin levels were
seen in the two groups of patients with impaired renal
function, as shown in Table 1. The patient group with
normal renal function had serum leptin levels comparable
to those in healthy controls. The correlation between GFR
and serum leptin levels in males and females, respectively,
are shown in Figure 2. The associations between GFR,
BMI and serum leptin in 219 patients with various degrees
of renal function are shown in Figure 3.
Low leptin gene expression in chronic renal failure
The ob gene expression was significantly lower in both
male (17.1 6 1.8 vs. 26.4 6 2.5 nCi/g; P , 0.05) and female
(16.2 6 1.2 vs. 26.2 6 2.4 nCi/g; P , 0.05) patients with
CRF than in BMI-matched healthy controls (Fig. 4). In
patients with terminal CRF, the serum leptin level was
23.8 6 5.4 ng/ml, and body composition analysis with DXA
revealed a body fat mass of 22.5 6 2.9 kg. A significant
positive correlation was observed between the serum leptin
levels and body fat mass (r 5 0.48; P , 0.05). The mean
serum leptin levels were 7.8 6 4.8 ng/ml in four healthy
males and 13.2 6 3.0 in four healthy females.
Elevated leptin gene expression in chronic renal failure
patients with inflammation
The ob gene expression (20.0 6 1.8 vs. 15.0 6 1.0 nCi/g;
P , 0.05) was significantly higher in five patients with
CRP . 25 mg/liter than in 10 age and BMI-matched
patients with CRP , 25 mg/liter, whereas the difference in
serum leptin levels (41.2 6 13.2 vs. 16.8 6 3.5 ng/ml) did
Table 1. Age, GFR, serum leptin and BMI in patients with normal renal function as well as moderate and advanced renal failure
Age years GFR ml/min Serum leptin ng/ml BMI kg/m2
Normal renal function (N 5 36) 43 6 2 98 6 2 10.0 6 1.0a 25.2 6 0.8
Moderate renal failure (N 5 79) 52 6 2c 51 6 2 16.9 6 1.5b 25.0 6 0.5
Advanced renal failure (N 5 104) 55 6 1d 10 6 1 27.7 6 3.6c 24.7 6 0.5
Data are mean 6 SEM.
a P , 0.01 vs. moderate renal function
b P , 0.05 vs. advanced renal failure
c P , 0.01 vs. normal renal failure
d P ,0.001 vs. normal renal function
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not attain statistical significance (P 5 0.08) with non-
parametric statistics (Fig. 5). A significant negative (r 5
20.66; P , 0.05) correlation was found between ob gene
expression and serum leptin levels in the group of patients
with CRP , 25 mg/liter but the relationship between the ob
gene expression and serum leptin levels did not attain
statistical significance (r 5 20.70; P 5 0.18) in five patients
with CRP . 25 mg/liter (Fig. 6). A significant positive
correlation was detected between CRP and serum leptin
levels (r 5 0.60; P , 0.05), but the relationship between
CRP and the ob gene expression (r 5 0.51; P 5 0.052) did
not attain statistical significance.
Changes in ob gene expression following 12 months of
peritoneal dialysis
Seven patients were re-investigated following 12 months
of PD. Body weight, body fat mass, serum leptin levels and
ob gene expression data are summarized in Table 2. At the
time point of re-examination following 12 months of PD,
two patients had moderately elevated CRP levels (14 and
24 mg/liter, respectively). Although no changes were ob-
served in the body wt, serum leptin levels and ob gene
expression, the body fat mass increased significantly (P ,
0.05) from 19.1 6 1.3 to 25.1 6 2.7 kg. The changes in ob
Fig. 2. The correlation between GFR and
serum leptin levels in males (V) (r 5 20.17;
P < 0.05; N 5 130) and females (v) (r 5
20.44; P < 0.0001; N 5 89), respectively.
Fig. 3. The relationship between serum leptin
levels and GFR in underweight (BMI < 20 kg/
m2), normal weight (BMI 20 to 25 kg/m2),
moderately overweight (BMI 25 to 30 kg/m2)
and overweight (BMI > 30 kg/m2) patients with
no (GFR > 80 ml/min), moderate (GFR 20 to
80 ml/min) and advanced (GFR < 20 ml/min)
renal impairment, respectively. Leptin
correlated independently with BMI (P ,
0.00001) and with GFR (P , 0.0002), but BMI
and GFR did not correlate with one another.
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gene expression following 12 months of PD correlated
significantly to the changes in body fat mass (r 5 0.94; P ,
0.01) and serum leptin levels (r 5 0.93; P , 0.01), as shown
in Figure 7.
DISCUSSION
In the present study we found markedly elevated serum
leptin levels in a large cohort of non-obese patients with
advanced renal failure (GFR , 20 ml/min), which confirms
recent findings in other human studies [9–12]. It has been
suggested that endogenous leptin is rapidly cleared from
the circulation by the kidney by glomerular filtration fol-
lowed by metabolic degradation in the renal tubules [17,
18]. Leptin has been reported to circulate in both a free
bioactive and a bound form in the human circulation [25].
Since protein binding has been found to be enhanced by
renal failure, it could be argued that the elevated serum
leptin levels demonstrated in the present study are due to
an excess of bound forms of leptin rather than free
bioactive forms. However, a recent study has shown that
elevated leptin levels in patients with advanced renal failure
are due to an increase in the free bioactive form of leptin
rather than in bound forms [11].
A novel finding in the present study is that male as well
as female patients with advanced renal failure have a
significantly lower expression of the ob gene than healthy
controls (Fig. 4). We have previously demonstrated that
expression of the human ob gene is markedly higher in
adipose tissue of massively obese subjects, which is another
group of patients with markedly elevated serum leptin
levels [22]. It has been suggested that resistance to the
biological effects of the increased leptin levels in obesity
may be secondary to an impaired transport of leptin over
the blood-brain-barrier [26, 27]. However, the mechanisms
underlying elevated serum leptin levels in patients having
renal failure probably differ from those causing elevated
levels in obese patients with normal renal function, in
whom there is a positive correlation between the adipose
expression of the ob gene and its secreted protein, leptin. In
the present study, however, the expression of the ob gene in
Fig. 4. Individual ob gene expression in male
(A) and female (B) patients with advanced
CRF, as compared to healthy controls. *P ,
0.05.
Fig. 5. Individual ob gene expression (A) and
serum leptin levels (B) in patients with
advanced CRF and CRP levels < 25 mg/liter
and > 25 mg/liter, respectively. *P , 0.05;
†P 5 0.08.
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adipose tissue correlated negatively to serum leptin levels
in patients with low CRP (Fig. 6). This suggests that
decreased plasma leptin clearance is a part of the efferent
feedback loop that down-regulates the expression of the ob
gene in hyperleptinemic patients with advanced CRF.
Although an inability of the kidneys to clear circulating
leptin is an important factor in the development of hyper-
leptinemia in renal failure, it must be recognized that other
factors such as increased fat mass, hyperinsulinemia and
inflammation also may contribute. Accordingly, in the
present study the main determinant of serum leptin levels
was BMI in both female and male patients, and about 30%
(that is, adjusted r2) of the variations in serum leptin levels
could be attributed to differences in BMI. We have previ-
ously presented data showing an excellent correlation
between body fat mass and serum leptin levels in patients
with advanced renal failure, and it can be concluded that fat
mass is the single most important determinant of serum
leptin levels also in patients with renal failure [8]. It is well
known that both leptin and insulin concentrations increase
with body fat mass [4] and it has been shown that long-term
(72 hr) insulin infusion stimulates leptin secretion [28, 29].
Impaired peripheral sensitivity to insulin and hyperinsulin-
emia are well recognized features of CRF [30]. Recently,
we demonstrated that although serum leptin levels are
markedly increased in CRF patients with elevated plasma
insulin levels, they are not increased in patients with low
plasma insulin levels, despite a similar degree of renal
impairment [16]. Comparable results have also recently
been presented by Shoji et al in patients having non-insulin-
dependent diabetes mellitus with various degrees of renal
impairment [19]. Altogether, these results suggest that
plasma insulin may be an important independent factor
Fig. 6. The correlations between ob gene expression and serum leptin
levels in 10 patients with CRP levels < 25 mg/liter (v) (r 5 20.66; P <
0.05) and 5 patients with CRP levels > 25 mg/liter (V) (r 5 20.70; P 5
0.18).
Table 2. Changes in body weight, body fat mass, serum leptin levels
and ob gene expression, following 12 months of peritoneal dialysis
Basal 12 months Significance
Body weight kg 70.3 6 4.6 72.6 6 5.8 NS
Body fat mass kg 19.1 6 1.3 25.1 6 2.7 P , 0.05
Serum leptin ng/ml 17.9 6 3.6 39.6 6 12.6 NS
Ob gene expression
nCi/g
15.4 6 1.4 15.2 6 1.9 NS
Data are mean 6 SEM. NS is not significant.
Fig. 7. The correlations between changes (D) in fat mass and ob gene
expression (r 5 0.94; P < 0.01) and changes in ob gene expression and
serum leptin levels (r 5 0.93; P < 0.01) in 7 patients with CRF following
12 months of peritoneal dialysis (PD). Symbols are: (f) females; (M)
males.
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affecting serum leptin levels in CRF. Another possible
reason for elevated serum leptin levels in renal failure is
chronic inflammation. We have previously found signifi-
cantly elevated serum leptin levels in CRF patients with
elevated CRP levels, indicating an ongoing inflammation
[8]. This finding prompted us to study the ob gene expres-
sion in CRF patients having high and normal CRP levels.
Interestingly, we found a significantly higher ob gene
expression in patients with CRP levels . 25 mg/liter than in
patients of similar age, BMI and GFR, but with CRP
levels , 25 mg/liter (Fig. 4). Accordingly, our findings
confirm results showing that cytokines such as tumor
necrosis factor-alpha (TNF-a) and interleukin (IL)-1 in-
duce both an increase in leptin mRNA levels and anorexia
in animals [31, 32]. Moreover, there is recent in vitro and in
vivo evidence that leptin secretion is regulated by TNF-a
[33], and, furthermore, Mantzoros et al have demonstrated
a significant independent relationship between serum lep-
tin and TNF-a in humans [34]. We have previously shown
that the 24-hour urinary urea excretion, indicating a lower
protein intake, is lower in CRF patients who have high
CRP levels [8]. Altogether, our results and the results
previously presented in animals [31, 32] raises the possibil-
ity that inflammation and activation of TNF-a may be one
of the mechanisms by which anorexia is induced during
inflammatory conditions. Since elevated levels of cytokines
are a common phenomenon in patients with renal failure
[35], it is tempting to speculate that the inflammatory
process in itself may contribute to a stimulation of ob gene
expression and thereby further increase the already high
circulating leptin levels in patients with CRF.
In the prospective part of the study, we showed that 12
months of PD treatment was associated with a significant
30% increase in body fat content. An increased body fat
mass following PD is a well-recognized feature [36] that is
probably caused by an increase in the continuous carbohy-
drate load [37]. In the present study, the increase in body
fat mass was not associated with an increase in ob gene
expression. However, strong positive correlations were
observed between changes in ob gene expression and
changes in both body fat mass and serum leptin levels,
following 12 months of PD. We find it interesting that the
regression line is shifted to the right in renal failure
compared to healthy controls, and that we detected an
increase in the ob gene expression only in patients with a
marked increase in their body fat mass (.6 kg) following 12
months of PD (Fig. 7). Thus, our present findings support
the concept that decreased plasma clearance, rather than
increased production, is the main cause of elevated serum
leptin levels in CRF, and that a feedback inhibition mech-
anism may exist that decreases leptin production from the
ob gene when elimination is impaired. However, it must be
pointed out that only a small number of patients were
studied prospectively, and although no general change in
ob gene expression was observed, inter-individual varia-
tions in ob gene expression were observed over the 12
month period.
In summary, the present study shows that patients with
moderate or advanced CRF have increased serum leptin
levels. We have also demonstrated a significantly lower ob
gene expression in patients with CRF, suggesting that
elevated serum leptin levels, due to decreased plasma
clearance, down-regulate the ob gene expression through a
negative feedback mechanism. The present results also
show that increased CRP levels, which indicate an ongoing
inflammatory response, stimulate adipose tissue ob gene
expression in patients with CRF.
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APPENDIX
Abbreviation used in this article are: BMI, body mass
index; CRF, chronic renal failure; CRP, C-reactive protein;
DXA, dual energy x-ray absorptiometry; GFR, glomerular
filtration rate; IL, interleukin; NPY, neuropeptide Y; PD,
peritoneal dialysis; TNF, tumor necrosis factor.
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